Practical approach to initiating SGLT2 inhibitors in type 2 diabetes

Thumbnail
View/Open
Issue date
2017
Author
Gomez-Peralta, Fernando
Abreu, Cristina
Lecube Torelló, Albert
Bellido, Diego
Soto, Alfonso
Morales, Cristóbal
Brito-Sanfiel, Miguel
Umpierrez, Guillermo
Suggested citation
Gomez-Peralta, Fernando; Abreu, Cristina; Lecube Torelló, Albert; Bellido, Diego; Soto, Alfonso; Morales, Cristóbal; ... Umpierrez, Guillermo. (2017) . Practical approach to initiating SGLT2 inhibitors in type 2 diabetes. Diabetes Therapy, 2017, vol. 8, núm. 5, p. 953-962. https://doi.org/10.1007/s13300-017-0277-0.
Impact

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
Sodium-glucose co-transporter 2 (SGLT2) inhibitors are an attractive novel therapeutic option for the treatment of type 2 diabetes. They block the reabsorption of filtered glucose in kidneys, mainly in proximal renal tubules, resulting in increased urinary glucose excretion and correction of the diabetes-related hyperglycemia. Beyond improving glucose control, SGLT2 inhibitors offer potential benefits by reducing body weight and blood pressure. On the basis of the efficacy demonstrated in clinical trials, SGLT2 inhibitors are recommended as second- or third-line agents for the management of patients with type 2 diabetes. Beneficial effects on kidney disease progression, cardiovascular and all-cause mortality, and hospitalization for heart failure have also been demonstrated with one SGLT2 inhibitor (empagliflozin). Potential adverse events resulting from their mechanism of action or related to concomitant therapies are reviewed. A treatment algorithm for the adjustment of concomitant therapies after initiating SGLT2 inhibitors is also proposed.
URI
http://hdl.handle.net/10459.1/60512
DOI
https://doi.org/10.1007/s13300-017-0277-0
Is part of
Diabetes Therapy, 2017, vol. 8, núm. 5, p. 953-962
Collections

The following license files are associated with this item:

cc-by-nc (c) Gomez-Peralta et al., 2017
Except where otherwise noted, this item's license is described as cc-by-nc (c) Gomez-Peralta et al., 2017